VERV
Price
$5.11
Change
-$0.50 (-8.91%)
Updated
Dec 18, 04:35 PM (EDT)
70 days until earnings call
ZLAB
Price
$26.14
Change
-$0.83 (-3.08%)
Updated
Dec 18, 04:37 PM (EDT)
76 days until earnings call
Ad is loading...

VERV vs ZLAB

Header iconVERV vs ZLAB Comparison
Open Charts VERV vs ZLABBanner chart's image
Verve Therapeutics
Price$5.11
Change-$0.50 (-8.91%)
Volume$38.43K
CapitalizationN/A
Zai Lab
Price$26.14
Change-$0.83 (-3.08%)
Volume$3.79K
CapitalizationN/A
VERV vs ZLAB Comparison Chart
Loading...
VERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
VERV vs. ZLAB commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VERV is a Hold and ZLAB is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (VERV: $5.61 vs. ZLAB: $26.97)
Brand notoriety: VERV and ZLAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: VERV: 113% vs. ZLAB: 29%
Market capitalization -- VERV: $474.96M vs. ZLAB: $2.86B
VERV [@Biotechnology] is valued at $474.96M. ZLAB’s [@Biotechnology] market capitalization is $2.86B. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

VERV’s FA Score shows that 1 FA rating(s) are green whileZLAB’s FA Score has 0 green FA rating(s).

  • VERV’s FA Score: 1 green, 4 red.
  • ZLAB’s FA Score: 0 green, 5 red.
According to our system of comparison, ZLAB is a better buy in the long-term than VERV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

VERV’s TA Score shows that 4 TA indicator(s) are bullish while ZLAB’s TA Score has 3 bullish TA indicator(s).

  • VERV’s TA Score: 4 bullish, 6 bearish.
  • ZLAB’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, VERV is a better buy in the short-term than ZLAB.

Price Growth

VERV (@Biotechnology) experienced а -16.52% price change this week, while ZLAB (@Biotechnology) price change was -2.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

VERV is expected to report earnings on Feb 26, 2025.

ZLAB is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZLAB($2.86B) has a higher market cap than VERV($475M). ZLAB YTD gains are higher at: -1.317 vs. VERV (-59.756). VERV has higher annual earnings (EBITDA): -219.97M vs. ZLAB (-297.74M). ZLAB has more cash in the bank: 616M vs. VERV (540M). VERV has less debt than ZLAB: VERV (71.3M) vs ZLAB (126M). ZLAB has higher revenues than VERV: ZLAB (356M) vs VERV (24.4M).
VERVZLABVERV / ZLAB
Capitalization475M2.86B17%
EBITDA-219.97M-297.74M74%
Gain YTD-59.756-1.3174,536%
P/E RatioN/AN/A-
Revenue24.4M356M7%
Total Cash540M616M88%
Total Debt71.3M126M57%
FUNDAMENTALS RATINGS
ZLAB: Fundamental Ratings
ZLAB
OUTLOOK RATING
1..100
70
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
45
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
VERVZLAB
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 10 days ago
87%
Bullish Trend 16 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
VERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RIEIX12.09N/A
N/A
RBC International Equity I
HDVSX12.40-0.06
-0.48%
Hartford International Equity R4
ADGYX25.23-0.14
-0.55%
AB Core Opportunities Advisor
LGLOX52.31-0.38
-0.72%
Lord Abbett Growth Leaders F3
CMGVX29.41-0.31
-1.04%
Columbia Select Mid Cap Gro Fd I2

VERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, VERV has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if VERV jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VERV
1D Price
Change %
VERV100%
+3.70%
BEAM - VERV
55%
Loosely correlated
-1.21%
CRSP - VERV
51%
Loosely correlated
+0.88%
NTLA - VERV
49%
Loosely correlated
-1.87%
EDIT - VERV
49%
Loosely correlated
+2.70%
RXRX - VERV
48%
Loosely correlated
-4.30%
More

ZLAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLAB has been loosely correlated with BGNE. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLAB jumps, then BGNE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLAB
1D Price
Change %
ZLAB100%
+3.02%
BGNE - ZLAB
43%
Loosely correlated
+1.55%
MDGL - ZLAB
38%
Loosely correlated
-1.58%
ADPT - ZLAB
36%
Loosely correlated
-3.83%
VERV - ZLAB
33%
Loosely correlated
+3.70%
GOSS - ZLAB
33%
Loosely correlated
+1.71%
More